Market research
CDX.AU CardieX Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 0.5
- Dividend yield
- Not available
- Beta
- 0.85
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- AU0000015729
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 0.5
- Dividend yield
- Not available
- Beta
- 0.85
About
About CardieX Limited
Conneqt Health Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffness indices. The company also provides medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders; and develops and sells medical devices, digital solutions, and wearables, home health, decentralized clinical trials, and remote patient monitoring. It sells its cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company was formerly known as CardieX Limited and changed its name to Conneqt Health Limited in September 2025. Conneqt Health Limited was founded in 1994 and is based in Sydney, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CDX.AU discussion.
5 years, 5 months ago
CardieX Limited is currently in a long term uptrend where the price is trading 7.6% above its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.9.
CardieX Limited's total revenue rose by 16.1% to $3M since the same quarter in the previous year.
Its net income has dropped by 5.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.0% to $-475K since the same quarter in the previous year.
Based on the above factors, CardieX Limited gets an overall score of 4/5.